Search

Anthony P Possemato

from Worcester, MA
Age ~45

Anthony Possemato Phones & Addresses

  • 32 Neptune Rd, Worcester, MA 01605 (508) 852-5036
  • Greene, NY
  • Framingham, MA
  • 141 Bowdoin St, Medford, MA 02155
  • 264 Kelton St, Allston, MA 02134 (617) 734-6672
  • Boston, MA
  • Greenburgh, NY
  • Cambridge, MA
  • 32 Neptune Rd, Worcester, MA 01605

Work

Company: Cell signaling technology (cst) Feb 1, 2005 Position: Research associate iv

Education

School / High School: Ithaca College 2001

Skills

Antibodies • Cell Biology • Biomarker Discovery • Elisa • Proteomics • Assay Development • Tissue Culture • Immunoassays • Transfection • Protein Chemistry • Purification • Cell Culture • Biochemistry • Monoclonal Antibodies • Cell Signaling • Western Blotting • Molecular Biology

Industries

Biotechnology

Resumes

Resumes

Anthony Possemato Photo 1

Research Associate Iv

View page
Location:
3 Trask Ln, Danvers, MA 01923
Industry:
Biotechnology
Work:
Cell Signaling Technology (Cst)
Research Associate Iv

Cell Signaling Technology (Cst)
Motif Antibody Development and Site Discovery
Education:
Ithaca College 2001
Greene Central School
Ithaca College
Skills:
Antibodies
Cell Biology
Biomarker Discovery
Elisa
Proteomics
Assay Development
Tissue Culture
Immunoassays
Transfection
Protein Chemistry
Purification
Cell Culture
Biochemistry
Monoclonal Antibodies
Cell Signaling
Western Blotting
Molecular Biology

Publications

Us Patents

Tyrosine Phosphorylation Sites

View page
US Patent:
7977462, Jul 12, 2011
Filed:
Apr 18, 2008
Appl. No.:
12/148547
Inventors:
Peter Hornbeck - Magnolia MA, US
Ailan Guo - Burlington MA, US
Klarisa Rikova - Reading MA, US
Albrecht Moritz - Salem MA, US
Charles Farnsworth - Concord MA, US
Matthew Stokes - Beverly MA, US
Jian Yu - Hamilton MA, US
Erik Spek - Cambridge MA, US
Yu Li - Andover MA, US
Anthony Possemato - Framingham MA, US
Jessica Cherry - Durham NH, US
Valerie Goss - Seabrook NH, US
Jeffrey Mitchell - Nashua NH, US
John Rush - Beverly MA, US
Corinne Michaud - Salem MA, US
Assignee:
Cell Signaling Technology, Inc. - Danvers MA
International Classification:
C07K 16/00
C12P 21/08
US Classification:
5303871, 5303877, 5303879, 5303881, 5303888, 53038885, 5303891, 5303897
Abstract:
The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.

Gene Defects And Mutant Alk Kinase In Human Solid Tumors

View page
US Patent:
8168383, May 1, 2012
Filed:
Oct 19, 2009
Appl. No.:
12/589176
Inventors:
Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Shrewsbury MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US
Assignee:
Cell Signaling Technology, Inc. - Danvers MA
International Classification:
C12Q 1/68
C12Q 1/48
C07H 21/00
C12N 9/12
US Classification:
435 61, 435194, 435 15, 536 231, 536 232, 536 235
Abstract:
Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

Gene Defects And Mutant Alk Kinase In Human Solid Tumors

View page
US Patent:
8232060, Jul 31, 2012
Filed:
Sep 3, 2009
Appl. No.:
12/584353
Inventors:
Klarisa Rikova - Reading MA, US
Herbert Haack - Holliston MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Burlington MA, US
Anthony Possemato - Framingham MA, US
Joan MacNeill - Derry NH, US
Assignee:
Cell Signaling Technology, Inc. - Danvers MA
International Classification:
G01N 33/53
C12P 21/00
C07K 14/00
C12Q 1/48
C12N 9/12
US Classification:
435 71, 435194, 435 691, 435 15, 530350
Abstract:
In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

Gene Defects And Mutant Alk Kinase In Human Solid Tumors

View page
US Patent:
8288102, Oct 16, 2012
Filed:
Feb 27, 2010
Appl. No.:
12/714457
Inventors:
Klarisa Rikova - Reading MA, US
Herbert Haack - Holliston MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Burlington MA, US
Anthony Possemato - Framingham MA, US
Joan MacNeill - Derry NH, US
Jian Yu - Hamilton MA, US
Assignee:
Cell Signaling Technology, Inc. - Danvers MA
International Classification:
C12Q 1/68
C12N 9/12
C07H 21/00
US Classification:
435 612, 435 61, 435194, 536 234, 536 243
Abstract:
In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

Gene Defects And Mutant Alk Kinase In Human Solid Tumors

View page
US Patent:
8377642, Feb 19, 2013
Filed:
Sep 28, 2010
Appl. No.:
12/891987
Inventors:
Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US
Assignee:
Cell Signaling Technology, Inc. - Danvers MA
International Classification:
C12Q 1/68
C07H 21/00
C12N 9/12
US Classification:
435 618, 435 614, 435 612, 435 611, 435194, 536 231, 536 232
Abstract:
In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

Translocation And Mutant Ros Kinase In Human Non-Small Cell Lung Carcinoma

View page
US Patent:
8383799, Feb 26, 2013
Filed:
Jul 18, 2008
Appl. No.:
12/218834
Inventors:
Ailan Guo - Burlington MA, US
Anthony Possemato - Worcester MA, US
Assignee:
Cell Signaling Technology, Inc. - Danvers MA
International Classification:
C07H 21/04
C12Q 1/68
G01N 33/53
C12P 21/02
C12N 15/09
C12N 5/10
C12N 1/21
A61P 35/00
C12N 1/15
C12N 15/63
C07K 14/47
C07K 16/18
A61K 31/713
US Classification:
536 234, 536 231, 536 235, 435 691, 435 697, 4353201
Abstract:
In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

Methods Of Treating Lung Cancer Using Inhibitors Anaplastic Lymphoma Kinase

View page
US Patent:
8481279, Jul 9, 2013
Filed:
Feb 6, 2012
Appl. No.:
13/366679
Inventors:
Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Shrewsbury MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US
Assignee:
Cell Signaling Technology, Inc. - Danvers MA
International Classification:
C12Q 1/48
A61K 31/00
C12N 9/12
US Classification:
435 15, 435194, 514 1
Abstract:
In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

Gene Defects And Mutant Alk Kinase In Human Solid Tumors

View page
US Patent:
8486645, Jul 16, 2013
Filed:
Apr 3, 2012
Appl. No.:
13/438218
Inventors:
Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Shrewsbury MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US
Assignee:
Cell Signaling Technology, Inc. - Danvers MA
International Classification:
G01N 33/53
G01N 33/563
C12Q 1/48
C12N 9/12
G01N 35/08
US Classification:
435 71, 435 15, 435194, 436512, 436513, 436 52
Abstract:
Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.
Anthony P Possemato from Worcester, MA, age ~45 Get Report